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Case presentation
A 74-year-old, previously healthy woman sought medical advice
because of multiple erythematous pustular skin lesions, which had
started on her hands and had progressed to her arms, back, abdomen,
chest, and legs. The patient had no history of renal dysfunction, renal
stones, diabetes mellitus, hypertension, urinary tract infections, or
analgesic abuse. She was taking no medications. She had no history of
documented hypotension, fever, or chills. The patient denied sore
throat, swollen glands, chest pain, shortness of breath, arthritis, and
seizures. She had had rheumatic fever when she was a child.
Physical examination on admission revealed a blood pressure of 140/
70 mm Hg; pulse, 80 beats per minute and regular; temperature, 98.6F,
and an estimated central venous pressure of 8 cm H20. Numerous
pustular lesions, most of which were crusted, were noted on the hands,
arms, trunk, buttocks, and soles. No adenopathy was present. The
chest was clear. Cardiac examination disclosed an S4, with no S3 or
pericardial friction rub. A grade TI/VI blowing diastolic murmur was
present at the left sternal border. No opening snap was heard. The
abdomen was soft and nontender without evidence of guarding or
rebound. The kidneys, liver, and spleen were not palpable. Moderate
left costovertebral angle tenderness was present. Rectal and pelvic
examinations were unremarkable, The stool was guaiac negative. There
was no peripheral edema and no evidence of active synovitis. The
patient was alert, oriented, and had full range of motion in a11 extrem-
ities; she had no localizing neurologic abnormalities. All reflexes were
equal and reactive throughout, with bilateral plantar responses.
Laboratory data on admission showed a hematocrit of 39.4%, a white
blood cell count of 17,300/mm3 with a normal thiferential, and a
sedimentation rate of 90 mm/hr. Sodium was 138 mEq/liter; potassium,
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3.9 mEq/liter; chloride, 101 mEq/liter; carbon dioxide, 24 mmollliter;
BUN, 16 mg/dl; creatinine, 1.1 mgldl; blood glucose, 101 mg/dl;
albumin, 4.3 gldl; globulin, 2.8 gIdl; uric acid, 4.8 mg/dl; calcium, 9.7
mg/dl; and phosphorus, 3.2 mg/dl. Liver function tests were normal.
Chest x-ray revealed clear lung fields without evidence of congestive
failure or infiltrate. The electrocardiogram was normal. Cultures of the
skin lesions grew group-A beta-hemolytic streptococci. A skin biopsy
showed impetigo and cellulitis without vasculitis. Six blood cultures
were negative.
The patient was initially treated with nafcillin, hut the medication was
changed to erythromycin after 3 days. The patient was oligurie during
the first hospital day, and the BUN climbed to 32 mg/dl over 4 days; the
creatinine rose to 4.2 mg/dl. Urinalysis on admission showed 3+
protein, occasional white cells, and scattered red cells. Numerous
granular and hyaline casts were noted; no red blood cell casts were
found. A Wright stain of the urine showed no eosinophils. Renal
ultrasound revealed normal-sized kidneys without obstruction; no
pelvic masses were noted. A urine culture was negative. Serum
cryoglobulins were negative. Complement levels were normal. An
antinuclear antibody test was positive at a ratio of 1:16 in a homoge-
neous pattern; an anti-DNA titer was negative. The antideoxyribonu-
clease B was positive, and serum immunoelectrophoresis was normal.
Rheumatoid factor was negative, as was an anti-GBM titer and a
hepatitis-B antigen.
In view of the rapid deterioration in the patient's renal function over a
one-week period and the concern over the possibility of postinfectious
glomerulonephritis, vasculitis, or rapidly progressive glomei-ulonephri-
tis, a renal biopsy was scheduled. Despite infusion of cryoprecipitate
and DDAVP, the bleeding time remained prolonged (greater than 15
minutes). For this reason, an open renal biopsy was performed. On two
occasions prior to the biopsy, a proximal tubular antigen assay revealed
elevated levels, at 0.89 and 1.6 assay units respectively.
Figures 1 and 2 show the biopsy results. On light microscopy, the
glomeruli appeared normal. This finding was confirmed on immunofiuo-
rescence and electron microscopy. Marked acute tubular injury was
present, however. The tubules showed sloughed, degenerated cells in
the lumen, basophilic cytoplasm, irregularly spaced nuclei, and several
mitoses. A few foci of interstitial infiltrate and edema were present.
The patient remained oliguric for 9 days after the biopsy (urine output
less than 400 ml/day) and thereafter the urine output slowly increased.
The serum creatinine peaked at II mg/dl but improved over the next
two weeks. The patient was discharged from the hospital with a serum
creatinine of 3 mg/dl. Serum creatinine stabilized over the next 4
months at 1.8 mg/dl.
Discussion
DR. NINA E. TOLKOFF-RUBIN (Chief Hemodialysis Unit,
Massachusetts General Hospital, and Assistanl Professor of
Medicine, Harvard Medical School, Boston, Massachusetts):
The patient presented here represents a common diagnostic
problem in clinical nephrology—acute oliguric renal failure in
an individual without a history of either intrinsic renal disease
or a systemic illness likely to affect the kidneys. The literature
tells us that when prerenal and postrenal causes of acute renal
failure (ARF) are eliminated from consideration, approximately
10% to 20% of such patients will have renal injury secondary to
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Fig. 1. Renal biopsy reveals normal-appearing glomeruli on light
microscopy and evidence of acute tubular injury.
acute glomerulonephritis, an acute vasculitis, or acute intersti-
tial nephritis [1]. The remainder have acute tubular necrosis
(ATN). If one differentiates between community-acquired ARF
(such as in this patient) and hospital-acquired ARF, one notes
an even higher incidence of acute glomerulonephritis, vasculi-
tis, or interstitial nephritis in the community-acquired cases [2,
3]. Indeed, in some populations, acute renal parenchymal injury
due to a disorder other than ATN accounts for more than 50%
of the cases of community-acquired ARF [1, 4]. In contrast,
virtually all the cases of intrinsic ARF that develop in the
hospital are due to ATN [2, 3].
Precisely diagnosing the cause of ARF in an individual
patient is of more than academic interest. Whereas treatment of
ATN unfortunately remains only supportive, specific therapy
does offer significant benefit for many of the other causes of
acute renal injury. Thus, immunosuppression and plasmaphere-
sis are effective in Goodpasture's syndrome; aggressive immu-
nosuppressive therapy is valuable in patients with Wegener's
granulomatosis, polyarteritis nodosa, and possibly rapidly pro-
gressive glomerulonephritis; and steroid therapy may be effica-
cious for certain forms of interstitial nephritis. All these clinical
entities share certain characteristics: (1) the rapidity with which
the diagnosis is made and therapy instituted is a critical factor in
determining the outcome of therapy; (2) the available therapies
have a high risk of side effects; and (3) differentiation of these
conditions both among themselves and from ATN can be quite
difficult, even with conventional laboratory tests such as urinal-
ysis, complement, serologic studies for collagen diseases, and
blood and urine chemistry determinations. Accordingly, pa-
tients such as this one with community-acquired ARF, who
might benefit from aggressive immunosuppressive therapy,
usually are subjected to renal biopsy. The purpose of such
biopsies is not only to define the nature of the disease process,
but also to define disease activity and potential reversibility.
Unfortunately, renal biopsies are not without hazard, and
even when initially successful they cannot be easily repeated to
assess the response to treatment. What has long been needed
for patients with acute renal failure is a group of noninvasive
diagnostic tests that can be repeated as often as circumstances
require. Such tests would help to define: (1) the anatomic site
Fig. 2. Renal biopsy (another field from the same biopsy shown in Fig.
I) reveals sloughed degenerated cells in the tubular lumen, irregularly
spaced nuclei along the tubule, and interstitial edema.
along the nephron that is affected, that is, glomerulus versus
proximal tubule, proximal tubule versus distal tubule, distal
tubule versus mesangium or interstitium; (2) the severity of the
renal injury; (3) the activity of the process, that is, is it
continuing to progress or is it "burned out?"; (4) the potential
responsiveness of the disease to therapy, and its response to
therapy; and (5) the state of the kidney in patients about to
receive nephrotoxic drugs or in renal transplant patients at risk
for allograft rejection. These diagnostic tests would constitute
an "early warning signal," when medical intervention could
limit the extent of the injury.
Many investigators have attempted to attain these objectives
over the past decades. Most of these researchers have devoted
their efforts to the measurement of low-molecular-weight plas-
ma proteins, such as beta-2-microglobulin in the urine or serum,
or to the determination of a variety of renal enzymes, such as L-
alanine aminopeptidase and N-acetyl-beta-D-glucosaminidase
(NAG) released into the urine following renal injury [5—9].
Although these tests have provided much useful information,
they have had limited application both because they are nonspe-
cific with regard to the cause and site of renal injury and
because the test proteins are not very stable in urine. Moreover,
a variety of enzyme inhibitors and other interfering materials
are present in the urine [10—13]. As a consequence, the specific-
ity of these tests among patients with varying forms of renal
disease is low. For example, although urinary NAG originates
from the lysosomes of proximal renal tubular cells, increased
levels are found not only in patients with ATN, but also in
patients with various forms of glomerular disease, obstructive
pyelonephritis, nephrosclerosis, and diabetic nephropathy [9,
14—211.
To improve the accuracy of noninvasive tests, several other
investigators have utilized the immunologic measurement of
specific renal antigens in the urine to determine the site and
severity of renal injury. Rosenmann and colleagues demonstrat-
ed renal antigens in urine samples of rats exposed to a variety of
renal toxins [221. Schoenfeld and Glassock, using an immuno-
diffusion technique, identified a proximal tubule brush-border
epithelial antigen in concentrated human urine, and first sug-
gested that a technique that could quantitate renal tubular
Current
designation
of antibody
Original published
antibody designation
Antigen
recognized
URO-1 J143 gp 140/120 30
URO-2 S4 gp 160
URO-3 F23 gp 140
URO-4 S27 gp 120
URO-4a S23 gp 120
URO-5 T16 gp 48/42
URO-7 S22 gp 115
URO-8 F31 -
URO-9 0M5 -
URO-lO T43 gp 85
Modified from Ref. 35.
antigen excretion might be a useful marker of tubular injury
[231. Zager and coworkers extended this work by developing a
radioimmunoassay for a proximal renal tubular epithelial anti-
gen (termed HRTE-1); the assay could be performed on voided
urine [24, 25]. They reported that 10 of 12 patients with ATN
had increased levels of this antigen in the urine, whereas 24
patients with chronic renal disease and 5 patients with prerenal
azotemia had levels that were indistinguishable from those in
normals. Because this antigen could be detected in other organs
and in sera of anephric patients, however, the specificity of this
assay is in doubt, Sachse, Falkenberg, Muller, and their col-
leagues reported similar findings, first with polyclonal antisera
and, more recently, with monoclonal antibodies directed
against renal epithelial cell antigens [26—28]. Rigorous correla-
tions of the results of such urinary assays in large numbers of
carefully defined patients with different renal diseases remain to
be accomplished, but the preliminary findings appear
promising.
Michael et a! described a group of monoclonal antibodies
(mAbs) that react with renal basement membranes, some of
which appear to be particularly useful for identifying the nature
of glomerular basement membrane antigens [29]. Thus far these
mAbs have been employed chiefly for mapping basement
membrane antigens, for delineating the ontogeny of antigen and
basement membrane development, and for exploring the identi-
ty of antigens at different sites within the kidney and in other
organs. Clearly, changes that occur in the distribution of these
Fig. 3. Distribution of different monoclonal
antibodies along the nephron (see Table 1).
Note that URO-7 and URO-9 (murine
monoclonal antibodies) do not react with
normal human kidney.
antigens and their expression during glomerular disease will be
of great importance.
We have taken a slightly different approach, one that utilizes
a series of monoclonal antibodies to renal and uroepithelial
antigens. These mAbs were generated by Dr. Lloyd Old and his
colleagues at the Memorial Sloan-Kettering Cancer Center. The
antibodies are prepared by fusing NS/l mouse myeloma cells
with spleen cells of mice immunized with cell lines of human
renal cancer, bladder cancer, and primary cultures of normal
adult kidney epithelium. The resulting mAbs have been invalu-
able for phenotyping tumors and for studying the ontogeny of
renal development [30—34]. In addition, 10 of these mAbs can
recognize surface glycoproteins of normal renal and urinary
tract epithelial cells in restricted areas and structures (Fig. 3,
Table 1)131, 34—36]. Because the nephron is bathed in urine, a
body fluid easily sampled, we hypothesized that if we could
develop assays using mAbs for one or more of these glycopro-
teins, we would have a quantitative means of determining both
the site and degree of nephron injury. In addition, because we
could easily obtain serial samples of urine, we postulated that
we could monitor the activity of the disease and its responsive-
ness to therapy.
Finding patients with proximal tubular injury from a wide
variety of causes is relatively easy, so we chose to test our
hypothesis by first designing an assay for a proximal tubular
antigen. Two commercially available murine mAbs, Uro-4 and
Uro-4a (trademark of Cambridge Research Laboratory, Cam-
bridge, Mass. 02139), recognize different epitopes (antigenic
determinants) of a 120,000 dalton glycoprotein, gp 120, which is
found on the brush border of the proximal tubular epithelial
cells. This gp 120 antigen recently was shown to be the
adenosine deaminase binding protein (ABP) [37]. We thus had
the opportunity to create a sandwich ELISA assay for quantify-
ing this antigen in the urine. The assay has five salient features
[38]: (1) Only 100 l of urine is needed for the assay; (2) The
antigen level remains stable at 37°C for greater than 3 hours at
the pH range encountered in urine (pH 5—9); (3) The antigen is
present in barely detectable quantities in normal individuals; (4)
Because purified ABP is not available, an arbitrary standard
curve has been generated that is linear from zero to two assay
units (AU), the range seen with most human disease, and which
has a precision similar to other sandwich immunoassays; (5)
When we compared random urine samples with aliquots from
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Table 1. Specific glycoproteins (gp) recognized by monoclonal
antibodies along the nephron
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Fig. 4. Results of urinary ABP assays in
patients with different forms of renal injury.
Open circles refer to greater than 4 days post
injury.
serial 24-hour urine collections from patients with elevated
antigen levels due to active renal disease, the coefficient of
variation was less than 20%. Because of the degree of separa-
tion between the level of ABP observed in urine specimens of
those with and without active acute tubular disease (Fig. 4) [39],
this degree of variation appears to be tolerable and is more than
made up for by the test's ability to generate clinically useful
information from analysis of a random urine sample. The data I
will present are derived from measurements made on random
urine samples unless otherwise noted. The ease of performing
this assay, the lack of interfering materials in the urine, and the
stability of ABP throughout the pH range found in human urine
all stand in contrast to the characteristics of previous assays for
detecting proximal tubular injury [10—13].
The ABP assay in patients with acute renal disease
The first step in assessing the utility of this assay was a
comparison of the values obtained from three groups: normal
controls, patients with glomerular disease, and patients with a
variety of acute tubular injuries. In each case the clinical
diagnosis was made without knowledge of the results of the
ABP assay. Similarly, the assay was performed without knowl-
edge of the clinical information.
The diagnosis of glomerular disease in all cases was con-
firmed by renal biopsy. These patients also had: (1) an elevated
BUN and serum creatinine concentration; (2) red blood cells or
red blood cell casts on urinalysis; and (3) a 24-hour urinary
protein excretion of greater than 1.5 g. The diagnosis of acute
tubular injury was made exlusively on clinical criteria. These
criteria included: (1) at least a doubling of the baseline serum
creatinine concentration; (2) an appropriate clinical setting
(documented hypotension, contrast media administration,
myoglobinuria, aminoglycoside administration for greater than
one week); (3) the presence of granular casts on urinalysis; and
(4) a urinary sodium concentration greater than 40 mEq/liter, or
a fractional excretion of sodium greater than 1% when
available.
All 37 normal controls had ABP values less than 0.1 AU, with
a mean value of 0.08 AU (Fig. 4). We have studied a total of 40
patients with glomeiular disease. Of these, 29(72.5%) had assay
values less than 0.2 AU, 9 (22.5%) had values of 0.2 to 0.4 AU,
Table 2. Results of urinary ABP assay in patients with different forms
of renal and urinary tract injury
Condition
No. of
patients
Assay
results (AU)a
1. Normal controls 37 <0.1
2. Glomerular disease 29
9
2
<0.2
0.2—0.4
0.4—0.6
3. Prerenal azotemia 8
2
<0.3
0.3—0.6
4. Postischemic acute
tubular necrosis 51
23
>1.0
0.6—1.0
(5 days postinjury) 5 0.4—0.6
5. Acute myoglobinuria 3 >1.0
6. Contrast-induced renal
failure 5 >1.0
7. Aminoglycoside toxicity 5 >1.0
8. Acute bacterial cystitis 12 <0.2
9. Acute bacteremic
pyelonephritis 6 >0.6
a AU refers to assay units.
and 2 (5%) had values of 0.4 to 0.6 AU. Biopsies from these last
2 patients, one with rapidly progressive glomerulonephritis and
one with active lupus glomerulitis, revealed evidence of severe
tubulointerstitial nephritis in addition to glomerular damage.
Mild to moderate degrees of tubulointerstitial inflammation
were demonstrable on biopsies from the 9 patients with glomer-
ular disease, whose ABP values were in the 0.2 to 0.4 AU
range. The small but statistically significant increase in urinary
ABP levels in patients with glomerular disease when compared
to that from controls is likely due to the glomerular leakage of
serum ABP, which, although low in the serum of normal
individuals, is present in these patients. It is likely that ABP
from the serum can appear in the urine in patients with
proteinuria (Table 2).
In contrast to the low levels found in normal individuals and
in patients with glomerular disease were those obtained in
patients with primary tubular disease. Of 79 patients with
postischemic ATN (defined as ATN following documented
hypotension), 51(64.6%) had assay values greater than 1.0 AU,
2.0-
LO-
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a,
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Fig. 5. Serial measurement of serum creatinine and urinary ABP levels
in a patient with acute proximal tubular injury following an episode of
acute rnyoglobinuria.
23 (29.1%) had values of 0.6 to 1.0 AU, and 5 (6.3%) had values
of 0.4 to 0.6 AU. Whereas the 74 patients in this group with
assay values greater than 0.6 AU all had been studied within 72
hours of renal injury, the 5 patients with the lowest values all
had been studied 5 days or more after an episode of hypoten-
sion. During this interval, serum creatinine levels remained
elevated in all patients. It seems likely that ABP levels are low 5
days or longer after an ischemic event because proximal tubular
injury is no longer active by that time.
This hypothesis gains credence from the serial studies in one
patient presented in Figure 5. The patient had proximal tubular
injury due to myoglobinuria. In this patient ABP values peaked
and returned to normal levels several days prior to the fall in
serum creatinine. Data from this patient and several others with
ARF due to various forms of proximal tubular injury suggest
that the serum creatinine (and BUN) are an incomplete measure
of the activity of renal parenchymal injury. It is known that in
the early postinjury period, serum creatinine levels can under-
estimate the extent of renal injury [40—42]. Data such as those in
Figure 5 suggest that serum creatinine measurements likewise
provide incomplete information in the late postinjury period;
that is, long after active tubular injury has ceased and clinical
recovery has begun, creatinine clearance remains unchanged.
In contrast, ABP release appears to occur promptly with acute
renal injury and is not obscured by the same factors that
influence the interpretation of serum creatinine when it is in the
1 to 3 mg/dl range. Similarly, ABP levels return toward normal
promptly with cessation of proximal tubular injury and inflam-
mation—often prior to falls in the serum creatinine.
The existence of high urinary ABP levels in patients with
ATN would be predicted from the anatomic localization of ABP
on the brush border of the proximal tubular epithelial cell.
Although postischemic ATN once was thought to evoke little
histologic change [43, 441, recent studies show that focal
necrosis of single proximal tubule cells and clusters of cells is
common [451. Even in otherwise apparently normal proximal
tubule cells subjected to ischemic injury, effacement of the
brush border is prevalent; this finding suggests that alteration of
the brush border is one of the earliest signs of ischemic
proximal tubule injury. Prompt release of brush-border antigen
: thus would be expected with acute injury [45—47].
One also would predict that ABP levels might be too sensitive
because they indicate minor tubular injury that is clinically
insignificant. We assessed the possibility that the ABP assay
might be overly sensitive by testing it in two clinical circum-
stances: in the differentiation of patients with prerenal azotemia
from those with ATN, and in the evaluation of patients receiv-
ing gentamicin therapy. Prerenal azotemia and postischemic
ATN, both of which arise from a combination of hypotension,
hypovolemia, and decreased renal perfusion, can be regarded
as two ends of a continuum. In prerenal azotemia, fixed damage
to the proximal tubule has not occurred, and the renal dysfunc-
tion can be corrected promptly by the restoration of circulatory
stability. In contrast, in ATN significant cellular injury has
taken place, and renal insufficiency cannot be immediately
corrected by the restoration of renal perfusion. Of 10 patients
studied thus far who had a clinical diagnosis of prerenal
azoteinia (on the basis of a consistent clinical picture, a BUN-
to-creatinine ratio greater than 15:1, a normal urinary sediment,
a urine sodium of less than 20 mEqfliter, or a fractional
excretion of sodium less than 1%), 8 had ABP levels in the urine
of less than 0.3 AU, and 2 had levels of 0.3 to 0.6 AU. Thus, in
the patient with circulatory instability, an assay of urinary ABP
levels appears to be a useful method for distinguishing between
ATN, that is, established structural renal injury, and prerenal
azotemia with potentially reversible physiologic abnormalities
and no structural damage. Particularly useful is the fact that in
our early experience, the urinary ABP assay does not appear to
be influenced by diuretic administration.
In contrast, the ABP assay appears to be less useful as a
predictor of imminent renal damage in patients receiving genta-
micin therapy. All 5 patients with clinically significant gentami-
cm toxicity (as defined by at least a doubling of the baseline
serum creatinine levels in a patient receiving gentamicin and
without other explanations for renal injury) had ABP levels well
above 1.0 AU. But patients receiving gentamicin therapy who
are without clinical evidence of toxicity likewise can have
elevated urinary ABP levels. Thus the value of a single determi-
nation in predicting clinical toxicity is limited. However, a
normal ABP assay in an azotemic patient receiving gentamicin
strongly suggests that the antibiotic is not the cause of the renal
insufficiency.
High ABP levels in conjunction with gentamicin toxicity are
not unexpected given the intrarenal events following gentamicin
administration. In vivo, after gentamicin is filtered by the
glomerulus into the tubular lumen, cellular uptake occurs, and
9 12
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initially gentamicin binds to the proximal tubule brush border
[48, 49]. In vitro, gentamicin binds to brush-border membrane
vesicles prepared from animal kidneys. Such binding is of
relatively low affinity and is saturable [50, 511. After binding to
the brush border, the drug is transported across the proximal
tubule cell membrane by pinocytosis and then concentrates
within lysosomes [52, 53]. Following intracellular accumula-
tion, toxic damage to the cell ensues by mechanisms still
incompletely understood. Accordingly, the brush border re-
ceives the brunt of gentamicin's effect long before the rest of the
proximal tubule epithelial cell does; thus it is no surprise that a
test that uses a brush-border antigen such as ABP would
overestimate the extent of gentamicin-induced cellular injury.
Increased urinary excretion of proximal tubule brush-border
enzymes such as NAG and alanine aminopeptidase following
gentamicin administration probably has the same significance
as the appearance of ABP [54, 55]. Two possible developments
could satisfy the need for an early warning of impending
toxicity in patients receiving aminoglycosides. The most likely
to succeed is an additional mAb-based assay that would mea-
sure a "deeper" proximal tubule cellular antigen that would be
shed only with greater cellular injury; alternatively, serial ABP
studies might yet reveal a pattern of release that is highly
predictive of toxicity.
We have begun to evaluate the ABP assay in one additional
class of intrinsic renal disease—pyelonephritis and urinary tract
infection. The clinical problem here is that not all urinary tract
infections are of equal importance or require similar forms of
therapy. Whereas pyelonephritis represents deep tissue infec-
tion at an anatomic site where antimicrobial delivery might be
difficult, cystitis represents superficial mucosal infection at an
anatomic site where high concentrations of antimicrobial drugs
easily can be attained. Unfortunately, the clinical or laboratory
markers that are currently available cannot accurately distin-
guish between pyelonephritis and cystitis [561. We have per-
formed ABP assays on a limited number of patients with full-
blown clinical pyelonephritis as opposed to patients with appar-
ent cystitis. All 6 patients with bacteremic pyelonephritis (as
defined by a syndrome of fever, chills, and flank pain, and the
same organism isolated from the urine and blood) had ABP
levels greater than 0.7 AU. In contrast, 12 women with appar-
ent cystitis (women who presented with dysuria and frequency,
had significant bacteriuria on urine culture, and were cured with
a single dose of antibiotic) all had urinary ABP levels less than
0.2 AU. Studies of patients with less extreme forms of pyelone-
phritis are in progress.
In sum, these first studies of a mAb-based assay for a
proximal tubule antigen in urine appear promising in differenti-
ating glomerular and tubular injuries. The patient presented
today underscores the need for a noninvasive test to distinguish
the various forms of renal disease. Clinicians caring for her had
made a tentative clinical diagnosis of postinfectious glomerulo-
nephritis, and had raised the possibility of rapidly progressive
glomerulonephritis or vasculitis, each of which might benefit
from immunosuppression with or without plasmapheresis. For
this reason, biopsy was performed, which revealed ATN in-
stead (Figs. 1 and 2). The urinary ABP levels prior to biopsy,
0.89 and 1.6 AU, had strongly suggested acute tubular injury.
The assay in this patient yielded the "correct" diagnosis
(defined by renal biopsy findings), whereas clinical and conven-
Fig. 6. Serialserum creatinine and urinary ABP levels, prednisone, and
azathioprine dosages in a patient undergoing uncomplicated cadaveric
renal transplantation.
tional laboratory evaluation had led to an incorrect diagnosis.
These initial results suggest that this approach has utility in
clinical decision-making.
The urinary ABP assay in renal transplantation
A noninvasive diagnostic test is badly needed in renal trans-
plant patients to accomplish the following tasks: (1) Provide
early warning of allograft rejection. This is particularly impor-
tant in children, in whom the small muscle mass exaggerates the
lack of sensitivity of serum creatinine measurements in diagnos-
ing early rejection; (2) Distinguish among the many forms of
allograft injury. Renal allograft dysfunction after transplanta-
tion can be due to the tubulointerstitial injury of cellular
rejection, vascular rejection associated with humoral factors,
technical complications of the transplant operation, postische-
mic ATN, drug toxicity such as that caused by cyclosporine or
gentamicin, glomerulopathy associated with cytomegalovirus
infection, pyelonephritis, and recurrent renal disease. Only the
first of these, cellular rejection, is likely to respond to increased
immunosuppressive therapy; (3) Provide a mechanism for mon-
itoring the effectiveness of antirejection therapy. Therapy of
acute cellular rejection with anti-thymocyte globulin (ATG) and
the pan-T cell murine mAb OKT3 reverses acute allogralt
rejection more rapidly and effectively than did earlier treat-
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ments. However, a recurrence of the rejection process within a
few days to weeks of completion of a course of such therapy is
common [57—60]. A test that would signal the presence of
recurrent rejection would be extremely useful because it would
allow us to take preventive measures quickly.
We therefore studied the potential usefulness of serial mea-
surement of urinary ABP levels in 34 patients undergoing renal
transplantation [61]. Figures 6 and 7 demonstrate that in pa-
tients undergoing renal transplantation not complicated by
acute rejection or drug toxicity, the urinary ABP level promptly
falls in the first week following transplantation to less than 0.4
AU and remains there. It does not matter whether immunosup-
pression consists of azathioprine and prednisone or cyclospor-
inc and prednisone.
We then studied 29 episodes of acute allograft rejection,
which we diagnosed clinically on the basis of a 50% or greater
increase in serum creatinine level over a period of less than 3
days that was not explained by some other cause. In 15 of these
episodes, the diagnosis was confirmed by the finding of typical
tubulointerstitial changes of cellular rejection on biopsy. The
diagnosis of rejection did not depend on the response to
therapy. All 29 episodes were associated with urinary ABP
levels greater than 0.6 AU, beginning I to 7 days prior to the
clinical diagnosis of rejection [391. Particularly noteworthy was
00 5 10 15 20
Time, days
o Fig. S. Clinical course of a pediatric recipient of an HLA-identical
kidney from a sibling. Serial serum creatinine and urinary ABP levels as
well as acute antirejection therapy are plotted, revealing the sustained
elevation in the urinary ABP level at least 5 days prior to any rise in
serum creatinine level and the occurrence of irreversible rejection.
the experience with the pediatric transplant recipient whose
course is outlined in Figure 8. In this patient, intermittent fevers
of uncertain origin and increased urinary ABP levels both began
more than 5 days prior to the time when the definitive diagnosis
of acute allograft rejection was made and treatment instituted.
By that time, it was too late to salvage the kidney, and the
patient had to return to chronic dialysis. We speculate that
rejection might have been reversed if immunosuppressive ther-
apy had been increased at the time when urinary ABP levels
began to increase.
A total of 18 patients with acute rejection (ABP levels greater
than 0.6 AU) were treated with either OKT3 or ATG and had a
"successful" reversal of their acute rejection process. In 6 of
these 18 treated patients, urinary ABP levels fell to less than
0.35 AU by the completion of the course of antirejection
therapy. None of these 6 rejected again over the next 3 months.
In contrast, 12 patients had high levels of urinary ABP (greater
than 0.6 AU) at the completion of antirejection therapy; 10 of
these had another rejection episode within 7 days of discontinu-
ing the ATG or OKT3 regimen. The course of one of these
patients is illustrated in Figure 9. In this patient, the acute
rejection episode initially responded to treatment with OKT3
and cyclophosphamide; the serum creatinine fell from a peak of
5 mgldl to 2.4 mgldl, but the ABP level continued to rise.
Another rejection episode ensued within 2 days of discontinua-
tion of the OKT3 regimen, and further therapy with ATG was
necessary. On that occasion, not only did the patient's serum
creatinine level fall, but the ABP level decreased as well, and he
has remained free of further rejection activity. In this case the
elevated ABP levels were a clue to ongoing rejection and the
need for further immunosuppressive therapy despite the initial
improvement in the serum creatinine. Subsequently, the fall in
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Fig. 7. Serial serum creatinine and urinary ABP levels, and cyclospor-
me and prednisone dosages in a patient undergoing uncomplicated
cadaveric renal transplantation.
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Fig. 9. Clinical course of an adult recipient of a cadaveric kidney.Serial serum creatinine and urinary ABP levels as well as acute
antirejection therapy are plotted. The first episode of rejection was
treated with OKT3 and cyclophosphamide, resulting in initial reversal
of the rejection process and a fall both in serum creatinine and urinary
ABP levels. By the end of the OKT3 treatment, however, the urinary
ABP level was still elevated, and the serum creatinine level began to
rise again shortly after the completion of the first course of antirejection
therapy. Treatment with ATG resulted in a sustained fall in both serum
creatinine and urinary ABP levels.
urinary ABP levels reflected reversal in the rejection episode
with ATG therapy.
We also studied 7 patients with "chronic allograft rejection"
who presented more than 6 months after transplantation with a
greater than 50% increase in serum creatinine level over a
period of more than 7 days. All these patients were subjected to
renal biopsy. Five had chronic vascular changes on biopsy,
with minimal evidence of tubulointerstitial inflammation, and
all 5 had urinary ABP levels less than 0.35 AU. None had a
clinical response to increased immunosuppressive therapy. The
other 2 patients had at least moderate amounts of tubulointersti-
tial inflammation on biopsy; the urinary ABP levels prior to
therapy were 0.79 and 0.96 AU respectively. Both patients
responded to increased immunosuppression with substantial
falls in their serum creatinine levels.
Of the original 34 patients studied, 15 were treated with
cyclosporine. Of these, 7 had no clinical evidence of allograft
rejection or cyclosporine toxicity. All 7 had urinary ABP levels
less than 0.35 AU, beginning approximately one week after
transplantation. In contrast, 8 patients had evidence of cyclo-
sporine toxicity (as defined by elevated serum creatinine levels
that fell more than 0.4 mgldl within 72 hours after the cyclospor-
me dose had been reduced). All 8 had urinary ABP levels
greater than 0.7 ALl that fell to normal within 36 hours after the
cyclosporine dose had been reduced.
These results must be considered preliminary, but they
strongly suggest that serial measurement of urinary ABP levels
might be useful in patients undergoing renal transplantation.
Such measurements appear to provide a reliable index of acute
rejection activity in three clinical contexts: the early diagnosis
of rejection, especially in pediatric transplant patients for whom
present diagnostic techniques are inadequate; the definition of a
subgroup of patients with "chronic rejection" who might
respond to increased immunosuppressive therapy, while pro-
tecting those who won't respond from the penalties of immuno-
suppression; and the assessment of the response of patients to
acute rejection therapy. This approach might provide a means
of individualizing an immunosuppressive regimen for each
patient—by not giving more immuosuppression than is needed,
but at the same time prescribing greater amounts to patients
1000 who require such therapy.It is clear that the urinary APB assay by itself is not the final
answer. The proximal tubule is the site of attack for many
0 pathologic processes after renal transplantation including ATN,
acute allograft rejection, and cyclosporine toxicity, and the
assay cannot be expected to distinguish among these. Deciding
whether the patient has either rejection or cyclosporine toxicity
is an extremely important clinical issue today. Ultimately, the
answer may lie in the development of other mAb-based as-
says—for example, for distal tubular or glomerular antigens—
that might allow one to distinguish among different pathogenetic
processes. In our limited experience, the urinary ABP level
appears to respond appropriately when the "correct" therapy is
selected; that is, if cyclosporine toxicity is the problem, and the
dose is decreased, the ABP level falls within 36 hours—often
before the serum creatinine level decreases. Alternatively, if
rejection is the problem, and increased immunosuppression is
instituted, the ABP levels often respond before the serum
creatinine does.
Application of monoclonal antibodies to the evaluation of
urinary tract malignancy
As I already have noted, the original reason for developing
the set of mAbs outlined in Figure 3 was to study malignant
disease. Renal cell carcinoma, a tumor of apparent proximal
tubule epithelial cell origin, has received the most attention thus
far. Not surprisingly, the mAbs that react with proximal tubular
antigens can be useful in tissue sections in distinguishing renal
from nonrenal tumors. In addition, much work has been done
with these reagents both on fresh tissue and cell lines from renal
cell carcinoma. These studies have sought to determine the
heterogeneity of the cellular populations within the tumor,
elucidate mechanisms of antigen expression and cellular differ-
entiation, and facilitate comparisons among fetal, normal adult,
and malignant kidney tissues in vitro and in vivo [31, 32, 34]. In
addition, these reagents are useful in phenotyping these tumors
into subsets that bear different combinations of the antigens
reactive with the mAbs URO-2 (S4), URO-4 (S27), URO-4a
(S23), and URO-7 (S22). Thus, certain tumors bear none of
these antigens; other tumors are positive for one or more of
these antigens. Preliminary data are consistent with the hypoth-
esis that such phenotyping of renal cell carcinomas will be
helpful in the clinical staging of patients and in predicting
prognosis (Bander NH, personal communication).
Recently, Klotz et al applied our ABP assay to the study of
OKT3 +
Cytoxa n __________________
0 ib 20 30
Time, days
t
500 tog SoIu-medrol
150 Nephrology Forum
sera from patients with renal cell carcinoma. Not only were
increased levels of ABP found in the sera of some of these
patients, but in those with an elevated level preoperatively,
measurement of the serum level in the postoperative period
correlated with the presence of residual disease [62].
The mAb approach has been extended to the study of bladder
cancer [33]. A series of mAbs has been generated, including
two, 0m5 (URO-9) and J233, which recognize antigens that
have not been found either on cultured cells of normal origin or
in normal adult or fetal tissue. Preliminary data indicate that
0m5 identifies bladder tumors of low-grade malignancy, where-
as other mAbs recognize antigens expressed in more aggressive
tumors. In addition to providing reagents for characterizing
tumors in tissue section, it is hoped that a mAb-based urinary
ELISA assay for detection and followup of bladder tumors will
result from this work.
Finally, preliminary work has suggested that one or more of
the renal cell carcinoma panel may be useful, when labeled with
a radioiodide, for tumor imaging [631. Not only would anatomic
delineation of the extent of the tumor by specific immune
imaging be clinically useful, but such results hold out the
tantalizing prospect of coupling a mAb to a cell toxin to
accomplish targeted" tumor therapy.
Conclusions
Murine mAbs directed against renal and urinary tract epithe-
hal cell antigens appear to have a great potential as diagnostic
tests for benign and malignant renal disease. At present, we
have reached the following conclusions:
1. The original hypothesis appears to be confirmed. That is,
monoclonal antibody-based assays directed against antigens
found in circumscribed portions of the nephron and performed
on urine specimens from patients with acute renal injury could
be quite useful in delineating the anatomic site of injury, the
severity of the injury, the activity of the process, and its
response to therapy.
2. The urinary ABP assay appears to be useful in the
diagnosis of acute renal failure of unknown cause, and in the
selection of therapy for patients with acute renal insufficiency
after renal transplantation.
3. The utility of the ABP assay should increase markedly
when a battery of mAb-based tests specific for other portions of
the nephron become available, and when the entire battery can
be directed against the urine excreted by a single patient. These
tests should be particularly useful in distinguishing diverse
forms of proximal tubule injury from each other such as ATN,
transplantation rejection, and cyclosporine toxicity, and as a
predictor of aminoglycoside toxicity.
4. The mAbs generated for urinary assay purposes might be
useful in the phenotyping of urinary tract cancer and in the
imaging of such cancer.
Questions and answers
DR. JOHN T. HARRINGTON: You mentioned in your talk some
of the other studies of urinary renal antigen extract using
different assays. Have direct comparisons been done of the
utility of other assays such as the Zager approach [56, 57]
versus your new approach? What is the advantage of your
approach?
DR. TOLKOFF-RUBIN: The general principle upon which the
assays are based is similar. But the nature of the antigen in
Zager's assay has not been reported. No direct comparison has
been made between the two assays. We believe that the
specificity inherent in a mAb-based assay adds important
advantages.
DR. HARRINOTON: What is the reproducibility of your assay
results? If you take one sample and run it repeatedly, how much
does the assay vary?
DR. RUSSELL THOMPSON (Cambridge Research Laboratory,
Cambridge, Mass.): The reproducibility is quite good, with no
more than 10% variability.
DR. HARRINOTON: Assuming that the usual reproducibility in
practice varies by 10% to 12%, is there anything in or about the
urine that can interfere with the assay, such as pyuria, urine
pH, or urine flow rate?
DR. TOLKOFF-RUBIN: As I pointed out earlier, the major
limitations of the presently available noninvasive studies, such
as /32 microglobulin and L-alanine aminopeptidase and N-acetyl
B-D glusosaminidase (NAG) assay, have been the presence of
enzyme inhibitors and interfering materials present in the urine,
such as the variety of enzymes liberated by white cells. In
contrast, white cells don't interfere with our monoclonal anti-
body assay for ABP. Moreover, unlike the /32-microglobulin
test, which is unstable below pH 6, the ABP assay remains
stable from pH 5 to 9, thus covering the physiologic pH range in
patients' urine. Likewise, urine flows at outputs greater than
200 cc/day don't appear to affect the validity of the assay, We
have not examined a sufficient number of patients with urine
outputs less than 200 cc/day to establish whether this degree of
oliguria affects the assay results.
The other major advantage of this assay is that it can be
performed on random samples, thus obviating the need for
obtaining 24-hour collections or first morning specimens.
DR. MICHAEL MADAIO (Division of Nephrology, NEMCH):
My questions pertain to the differentiation between tubular and
glomerular diseases. Did the patients with glomerular disease
have the same degree of renal insufficiency as did those with
ATN? Furthermore were the patients matched for duration of
disease? We usually have the opportunity to evaluate patients
very early in the course of ATN, whereas patients with glomer-
ular disease typically present to the physician later in the
course.
DR. TOLKOFF-RUBIN: This question is difficult to answer
because, as you point out, we frequently can date the onset of
the tubular injury, but it is usually impossible to do so for the
glomerular disease. Nonetheless, whether at similar or different
serum creatinine levels, we have been able to distinguish
between glomerular and tubular disease.
DR. RONALD PERRONE (Division of Nephrology, NEMCI-I):
In the presentation of patients with urinary tract infection, you
selected two very clearly defined groups of patients. Have you
had any experience with patients in whom it is clinically difficult
to distinguish upper from lower urinary tract infection?
DR. TOLKOFF-RUBIN: That is exactly the question we are
looking at. The data are unavailable at present, however.
DR. PERRONE: What is the effect of prostatitis on the assay?
DR. TOLKOFF-RUBIN: We have examined 15 patients with
prostatitis and in all cases the ABP levels were within the
normal range.
DR. HARRINGTON: You discussed distinguishing prerenal
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azotemia from acute tubular necrosis in a study of a limited
number of patients. Have you extended that group, and do your
conclusions still hold?
DR. TOLKOFF-RUBIN: Our initial group of 10 patients with
prerenal azotemia strictly conformed to our diagnostic criteria.
We subsequently have studied an additional 6 patients with
prerenal azotemia and they likewise have demonstrated low
levels of ABP in the urine.
DR. ELEANOR PACKMAN (Renal Fellow, NEMCH): Do ABP
levels remain elevated in patients with prolonged ATN, or
rather, can levels be used to predict who will recover from ATN
and who will not?
DR. ROBERT RUBIN (Chief of Infectious Disease for Trans-
plantation, Massachusetts General Hospital): This is an impor-
tant question for which we don't yet have enough information
to provide an answer. Our hypothesis is that the degree of ABP
elevation over a particular time interval will be proportional to
the extent of proximal tubular injury and thus will be a
prognostic indication. Indeed, our data in transplant patients
would suggest that this is true: patients with acute rejection and
only a moderate elevation of ABP level appear to respond much
more quickly and more completely than do those with more
extreme elevations, particularly if these elevations are sus-
tained. Our data in patients with ATN are still too fragmentary
for comment.
DR. HARRINGTON: Do you have enough confidence in the
method to use it clinically? In particular, in a pediatric patient in
whom acute rejection is so difficult to diagnose, would you not
treat the patient if the assay result is 1.2 AU?
DR. TOLKOFF-RUBIN: As we are gaining more experience
correlating the assay with biopsy specimens, particularly in the
transplant patients, we indeed are becoming more confident of
its clinical utility in making therapeutic decisions.
DR. PERRONE: Have you developed any antibodies to distal
nephron structures?
DR. TOLKOFF-RUBIN: Yes, but we have not devised a format
for an assay yet.
DR. NIc0LA0s E. MADIAS: What is the projected cost of the
assay?
DR. TOLKOFF-RUBIN: About $2.00 per test.
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